Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (661-670 of 850) with videos related to

Pageof 85
Sort By:
European Urology|October 3, 2006
Development and external validation of an extended 10-core biopsy nomogramFelix K-H Chun, Alberto Briganti, Markus Graefen, et al.
The Prostate|February 21, 2022
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groupsBenedikt Hoeh, Christoph Würnschimmel, Rocco Simone Flammia, et al.
The Prostate|February 21, 2022
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patientsBenedikt Hoeh, Rocco S Flammia, Lukas Hohenhorst, et al.
Clinical Genitourinary Cancer|February 2, 2024
The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma PatientsReha-Baris Incesu, Francesco Barletta, Cristina Cano Garcia, et al.
Annals of Surgical Oncology|May 21, 2024
Sarcomatoid Dedifferentiation as a Predictor of Cancer-Specific Mortality in Surgically Treated Localized Renal Cell CarcinomaReha-Baris Incesu, Simone Morra, Lukas Scheipner, et al.
Central European Journal of Urology|July 24, 2023
The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancerFrancesco Chierigo, Rocco Simone Flammia, Gabriele Sorce, et al.
Diagnostics (Basel, Switzerland)|May 13, 2023
External Tertiary-Care-Hospital Validation of the Epidemiological SEER-Based Nomogram Predicting Downgrading in High-Risk Prostate Cancer Patients Treated with Radical ProstatectomyCristina Cano Garcia, Mike Wenzel, Mattia Luca Piccinelli, et al.
The Prostate|September 15, 2021
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Frontiers in Oncology|December 10, 2021
Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer PatientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Oncotarget|August 22, 2015
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancerMartina Kluth, Ramin Ahrary, Claudia Hube-Magg, et al.
Pageof 85

Showing results (661-670 of 850) with videos related to

Sort By:
Pageof 85
European Urology|October 3, 2006
Development and external validation of an extended 10-core biopsy nomogramFelix K-H Chun, Alberto Briganti, Markus Graefen, et al.
The Prostate|February 21, 2022
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groupsBenedikt Hoeh, Christoph Würnschimmel, Rocco Simone Flammia, et al.
The Prostate|February 21, 2022
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patientsBenedikt Hoeh, Rocco S Flammia, Lukas Hohenhorst, et al.
Clinical Genitourinary Cancer|February 2, 2024
The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma PatientsReha-Baris Incesu, Francesco Barletta, Cristina Cano Garcia, et al.
Annals of Surgical Oncology|May 21, 2024
Sarcomatoid Dedifferentiation as a Predictor of Cancer-Specific Mortality in Surgically Treated Localized Renal Cell CarcinomaReha-Baris Incesu, Simone Morra, Lukas Scheipner, et al.
Central European Journal of Urology|July 24, 2023
The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancerFrancesco Chierigo, Rocco Simone Flammia, Gabriele Sorce, et al.
Diagnostics (Basel, Switzerland)|May 13, 2023
External Tertiary-Care-Hospital Validation of the Epidemiological SEER-Based Nomogram Predicting Downgrading in High-Risk Prostate Cancer Patients Treated with Radical ProstatectomyCristina Cano Garcia, Mike Wenzel, Mattia Luca Piccinelli, et al.
The Prostate|September 15, 2021
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Frontiers in Oncology|December 10, 2021
Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer PatientsBenedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
Oncotarget|August 22, 2015
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancerMartina Kluth, Ramin Ahrary, Claudia Hube-Magg, et al.
Pageof 85